Sanofi

AMEERA-3 | ACT16105

NCT04059484

JCP067

Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Status:

Closed to Accrual

26459-200.png

II

Phase

Line of Therapy.png

2nd

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

ER+, HER2-

Investigational

Product

SAR439859

Selective Estrogen Degrader (SERD), p.o.

Treatment Arms

SAR439859 vs Control treatment of the choice of the physician (1:1):

o Fulvestrant
o Aromatase inhibitors (anastrozole, letrozole, exemestane)
o Selective estrogen receptor modulator (Tamoxifen)